dose otcqb rdtcf advances quickstrip b resea

DOSE) (OTCQB: RDTCF) Advances QuickStrip™ Research Backed by NFL … – StreetInsider

✦ New
CED Clinical Relevance
#58 Clinical Context
Background information relevant to the evolving cannabis medicine landscape.
ResearchCBDDosingSafetyIndustry
Why This Matters
If thin-film CBD delivery is confirmed to offer superior and more consistent bioavailability compared to traditional oral products, patients may need to recalibrate their doses when switching formats to avoid unintended underdosing or overdosing.
Clinical Summary

Sublingual and buccal thin-film delivery systems represent a meaningful departure from conventional oral cannabinoid formats because they bypass first-pass hepatic metabolism, potentially improving both the speed of onset and the consistency of systemic absorption. CBD delivered through mucoadhesive strip technology may achieve higher bioavailability compared to standard oil-based or capsule formulations, which are notoriously variable due to differences in fed versus fasted states and individual digestive physiology. Rigorous comparative bioavailability studies are exactly what the field needs to move cannabinoid dosing from approximation toward precision.

Dr. Caplan’s Take
“Bioavailability data for cannabinoids has been embarrassingly thin for decades, and any well-controlled study that quantifies absorption differences across delivery formats is a genuine contribution to rational dosing.”
Clinical Perspective

🔬 The bioavailability comparison between rapid-onset delivery systems and traditional oral CBD formats addresses a genuine clinical gap. Current evidence suggests that oral CBD absorption is highly variable due to first-pass metabolism and food-drug interactions, making alternative delivery routes clinically relevant. Sublingual or mucosal delivery methods may offer more consistent plasma levels and potentially faster symptom onset, which could be advantageous for acute symptom management. Well-designed pharmacokinetic studies in this space help establish whether novel delivery mechanisms provide measurable clinical benefits beyond convenience. However, clinical efficacy data in relevant patient populations remains the critical next step before drawing conclusions about therapeutic superiority.

💬 Join the Conversation

Have a question about how this applies to your situation? Ask Dr. Caplan →

Want to discuss this topic with other patients and caregivers? Join the forum discussion →